Second Genome

OverviewSuggest Edit

Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
HQSouth San Francisco, US
Employee Ratings5

Latest Updates

Employees (est.) (Jan 2020)48(-4%)

Key People/Management at Second Genome

Karim Dabbagh

Karim Dabbagh

President, Director and Chief Executive Officer
Corey S. Goodman

Corey S. Goodman

Co-Founder and Chair of the Board
Todd DeSantis

Todd DeSantis

Co-Founder and Vice President, Informatics
Mike Carusi

Mike Carusi

Board Member
Anu Hoey

Anu Hoey

Chief Business Officer
Bill Burkoth

Bill Burkoth

Board Member
Show more

Second Genome Office Locations

Second Genome has an office in South San Francisco
South San Francisco, US (HQ)
341 Allerton Ave
Show all (1)

Second Genome Financials and Metrics

Summary Metrics

Founding Date


Second Genome total Funding

$76.5 m

Second Genome latest funding size

$8.40 m

Time since last funding

4 years ago

Second Genome investors

Second Genome's latest funding round in July 2016 was reported to be $8.4 m. In total, Second Genome has raised $76.5 m
Show all financial metrics

Second Genome Online and Social Media Presence

Embed Graph

Second Genome News and Updates

FORTUNE and Great Place to Work Name Second Genome a "Top 10 Best Workplace in Biopharma"

SOUTH SAN FRANCISCO, Calif., April 9, 2019 /PRNewswire/ -- FORTUNE and Great Place to Work have honored Second Genome as one of the 2019 Top 10 Best Workplaces in Biopharma. The ranking considered feedback representing almost 730,000 employees working at Great Place to Work-Certified...

Second Genome Appoints Anupama S. Hoey as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., July 23, 2018 /PRNewswire/ -- Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer. In her role, Ms. Hoey will be leading all...

Second Genome Frequently Asked Questions

  • When was Second Genome founded?

    Second Genome was founded in 2009.

  • Who are Second Genome key executives?

    Second Genome's key executives are Karim Dabbagh, Corey S. Goodman and Todd DeSantis.

  • How many employees does Second Genome have?

    Second Genome has 48 employees.

  • Who are Second Genome competitors?

    Competitors of Second Genome include PanTheryx, Novacyt and Palleon Pharmaceuticals.

  • Where is Second Genome headquarters?

    Second Genome headquarters is located at 341 Allerton Ave, South San Francisco.

  • Where are Second Genome offices?

    Second Genome has an office in South San Francisco.

  • How many offices does Second Genome have?

    Second Genome has 1 office.